Literature DB >> 15057909

Analyses of hepatocellular proliferation in a mouse model of alpha-1-antitrypsin deficiency.

David A Rudnick1, Yunjun Liao, Jae-Koo An, Louis J Muglia, David H Perlmutter, Jeffrey H Teckman.   

Abstract

alpha-1-Antitrypsin (alpha1-AT) deficiency is the most common cause of metabolic pediatric liver disease. Hepatocellular injury is caused by toxicity of the mutant alpha-1-antitrypsin Z (alpha1-ATZ) molecule retained within hepatocytes. In these studies, we used the PiZ transgenic mouse model of alpha1-AT deficiency to examine hepatocellular proliferation in response to chronic liver injury resulting from this metabolic disease. The results showed increased hepatocellular proliferation and caspase 9 activation in male PiZ mice compared with female PiZ and wild-type mice. Hepatic alpha1-AT mRNA and protein expression also were increased in male PiZ mice, suggesting that greater hepatocellular proliferation and caspase activation in males results from increased hepatotoxicity associated with greater intracellular alpha1-ATZ accumulation. Testosterone treatment of female PiZ mice increased alpha1-ATZ expression and hepatocellular proliferation to a level comparable with that in males. In PiZ mice, hepatocytes devoid of intracellular alpha1-AT globules had a proliferative advantage compared with globule-containing hepatocytes. However, this advantage is relative because both globule-containing and globule-devoid hepatocytes exhibited comparable proliferation after partial hepatectomy. In conclusion, these data indicate that intracellular retention of mutant alpha1-ATZ is associated with a regenerative stimulus leading to increased hepatocellular proliferation, that gender-specific signals influence the degree of alpha1-AT expression and associated hepatic injury, and that hepatocytes devoid of alpha1-ATZ have a proliferative advantage over cells that accumulate the mutant protein. This selective proliferation suggests that hepatocellular transplantation may be applicable for treatment of this and other slowly progressive metabolic liver diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15057909     DOI: 10.1002/hep.20118

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  41 in total

Review 1.  Novel treatment strategies for liver disease due to α1-antitrypsin deficiency.

Authors:  Nicholas Maurice; David H Perlmutter
Journal:  Clin Transl Sci       Date:  2012-01-10       Impact factor: 4.689

2.  Hepatic progenitor cell proliferation and liver injury in α-1-antitrypsin deficiency.

Authors:  Elizabeth M Brunt; Keith Blomenkamp; Muneeb Ahmed; Faiza Ali; Nancy Marcus; Jeffrey Teckman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-11       Impact factor: 2.839

Review 3.  Liver repopulation and carcinogenesis: two sides of the same coin?

Authors:  Fabio Marongiu; Silvia Doratiotto; Stefania Montisci; Paolo Pani; Ezio Laconi
Journal:  Am J Pathol       Date:  2008-03-05       Impact factor: 4.307

Review 4.  Elucidating the metabolic regulation of liver regeneration.

Authors:  Jiansheng Huang; David A Rudnick
Journal:  Am J Pathol       Date:  2013-10-17       Impact factor: 4.307

5.  NFκB mitigates the pathological effects of misfolded α1-antitrypsin by activating autophagy and an integrated program of proteostasis mechanisms.

Authors:  Amitava Mukherjee; Tunda Hidvegi; Patrick Araya; Michael Ewing; Donna B Stolz; David H Perlmutter
Journal:  Cell Death Differ       Date:  2018-05-23       Impact factor: 15.828

6.  Z α-1 antitrypsin deficiency and the endoplasmic reticulum stress response.

Authors:  Catherine M Greene; Noel G McElvaney
Journal:  World J Gastrointest Pharmacol Ther       Date:  2010-10-06

Review 7.  α1-antitrypsin deficiency and the hepatocytes - an elegans solution to drug discovery.

Authors:  Linda P O'Reilly; David H Perlmutter; Gary A Silverman; Stephen C Pak
Journal:  Int J Biochem Cell Biol       Date:  2013-12-17       Impact factor: 5.085

8.  Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice.

Authors:  Shuling Guo; Sheri L Booten; Mariam Aghajan; Gene Hung; Chenguang Zhao; Keith Blomenkamp; Danielle Gattis; Andrew Watt; Susan M Freier; Jeffery H Teckman; Michael L McCaleb; Brett P Monia
Journal:  J Clin Invest       Date:  2013-12-20       Impact factor: 14.808

Review 9.  Advances in alpha-1-antitrypsin deficiency liver disease.

Authors:  Jeffrey H Teckman; Ajay Jain
Journal:  Curr Gastroenterol Rep       Date:  2014-01

10.  Pathophysiology and fate of hepatocytes in a mouse model of mitochondrial hepatopathies.

Authors:  F Diaz; S Garcia; D Hernandez; A Regev; A Rebelo; J Oca-Cossio; C T Moraes
Journal:  Gut       Date:  2007-10-19       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.